[丙卡巴肼、长春新碱和洛莫司汀联合治疗（PCV方案）在少突胶质细胞瘤和混合性胶质瘤中的评估]
[Assessment of procarbazine, vincristine and lomustine association (PCV protocol) in oligodendroglioma and mixed glioma].
作者信息
Bouffet E, Mornex F, Jouvet A, Thiesse P, Mertens P, Helfre S, Sindou M, Bret P
机构信息
Département de neurooncologie, Centre Léon-Bérard, Lyon, France.
出版信息
Bull Cancer. 1997 Oct;84(10):951-6.
Effective chemotherapy using PCV (procarbazine, lomustine and vincristine) has been documented in anaplastic oligodendrogliomas and oligoastrocytomas. A pilot study using PCV was conducted for relapsing patients with anaplastic oligodendrogliomas and oligoastrocytomas. Preliminary results are reported. Fourteen patients were enrolled. All received at least two courses of PCV and were evaluable for response. Eleven patients (78%) responded to chemotherapy with complete responses in 2 patients. Response was more obvious regarding contrast enhanced areas than volumes changes (11 responses versus 7). A story of seizure was the main clinical prognostic factor for response. All toxicities were manageable and no treatment related death occurred. Chemotherapy is an effective treatment in aggressive oligodendrogliomas. Further studies must assess the role of chemotherapy in the multidisciplinary management of oligodendroglioma.
使用PCV（丙卡巴肼、洛莫司汀和长春新碱）进行的有效化疗已在间变性少突胶质细胞瘤和少突星形细胞瘤中得到证实。对复发性间变性少突胶质细胞瘤和少突星形细胞瘤患者开展了一项使用PCV的试点研究。报告了初步结果。纳入了14例患者。所有患者均接受了至少两个疗程的PCV治疗，并可评估疗效。11例患者（78%）对化疗有反应，其中2例完全缓解。对比增强区域的反应比体积变化更明显（11例有反应 vs 7例）。癫痫发作史是反应的主要临床预后因素。所有毒性均可控制，未发生与治疗相关的死亡。化疗是侵袭性少突胶质细胞瘤的有效治疗方法。进一步的研究必须评估化疗在少突胶质细胞瘤多学科管理中的作用。
Zotero 插件